

**Supply or Administration**  
**PATIENT GROUP DIRECTION (PGD) FOR**




**LORAZEPAM 1MG TABLETS**

**YOU MUST BE AUTHORISED BY NAME, UNDER THE CURRENT VERSION OF THIS PGD BEFORE YOU ATTEMPT TO WORK ACCORDING TO IT**

| <b>Clinical Condition</b>  |   |
|--|---|
| <b>Indication</b>  | Patients displaying severe agitation and/or severe anxiety  |
| <b>Inclusion criteria</b>  | Patients of 16 years of age and older   |
| <b>Exclusion criteria</b><br>If any of the following apply the PGD CANNOT be used and the patient must be referred to a prescriber | Under 16 years old.<br>Established benzodiazepine dependence or hypersensitivity to any benzodiazepine agent<br>Patient requiring Rapid Tranquillisation (not covered by PGD)<br>Acute pulmonary insufficiency, respiratory depression<br>Sleep apnoea. Severe hepatic insufficiency.<br>Possible pregnancy. Obsessional states. Myasthenia Gravis.   |
| <b>Cautions - Seek further advice from doctor before proceeding and document advice</b>  | Elderly patients are more prone to side effects eg hypotension so care if pre-existing cerebral or cardiovascular problems.<br>Patients who have consumed alcohol within the last 24 hours.<br>Patients taking other CNS depressants or sedatives<br>Risk of disinhibited behaviour<br>Patients with COPD or similar chronic respiratory disorders<br>Taking medicines known to interact with lorazepam (see BNF) |
| <b>Further information</b>   | Grapefruit juice and some drugs affecting liver enzymes can increase the sedative effect of lorazepam (see SPC & BNF)   |
| <b>Action if patient declines or is excluded</b>   | Refer to doctor if patient cannot be treated under PGD<br>Document refusal or action taken in patient's records   |
| <b>Drug Details</b>  |   |
| <b>Name, form &amp; strength of medicine</b>   | Lorazepam 1mg tablet  |
| <b>Legal status</b>  | POM   |
| <b>Route/Method</b>  | Oral  |
| <b>Dosage &amp; Frequency</b>  | <b>Age 16-75 years</b> - 1mg every 2 hours up to a maximum dose of 4mg (4 doses) in 24 hours.<br><b>Age over 75 years</b> - 0.5mg (half a tablet) every 2 hours up to a maximum dose of 2mg (4 doses) within 24 hours.<br>ONE repeat use of this PGD is permitted during the 7 days following its first use.  |
| <b>Quantity to Supply or Administer</b>  | Supply for patient to take home: A pack of 4 x 1mg Lorazepam tablets. If 0.5mg dose is being used, remaining tablets should be discarded unless PGD is repeated.<br>Administration on site: from ward stock   |
| <b>Side effects</b>  | Drowsiness; light-headedness; muscle weakness; possible impairment of memory for recent events. If adverse effects occur the patient should consult their clinic, GP, A&E for advice.   |
| <b>Advice to patient/carer</b>   | Patients should be advised that sedation, amnesia, impaired concentration, dizziness, blurred vision and impaired muscular  |

**Supply or Administration  
PATIENT GROUP DIRECTION (PGD) FOR**

**LORAZEPAM 1MG TABLETS**

|  |   |
|--|---|
|  | function may occur. Avoid driving or operating machinery.   |
| <b>Staff Characteristics</b>                     |   |
| <b>Professional qualifications</b>               | Mental Health Nurses on NMC register (Band 5 and above)   |
| <b>Specialist competencies or qualifications</b> | A nurse as above, (after discussion and agreement with the service/departmental lead) who has undertaken training in and attended annual updates on and is therefore competent to supply and administer medicines under PGDs and is trained to carry out clinical assessment of patients leading to diagnosis that requires treatment according to the indications listed here.   |
| <b>Continuing education &amp; training</b>       | It is the responsibility of the individual to keep up-to-date with clinical developments as part of their continued professional development.   |
| <b>Referral Arrangements and Audit Trail</b>     |   |
| <b>Records/audit trail</b>                       | Patient's name, address, date of birth, contact details of GP (if registered), diagnosis.<br>Dose and form supplied or administered<br>Advice given to patient (including side effects).<br>Signature/name of staff who supplied the medication.<br>Details of any adverse drug reaction and actions taken including documentation in the patient's medical record.<br>Referral arrangements (including self-care)<br>Record use of this PGD in Pre-Packed medicines register or on a ward log sheet. |
| <b>References/Resources and comments</b>         | Current versions of Summary of Product Characteristics & BNF  |
| <b>Development &amp; Clinical Authorisation</b>  |   |
| <b>Lead Doctor</b>                               | Dr John Devapriam, Medical Director<br><br>Signature:  Date: 27/9/18   |
| <b>Lead Pharmacist</b>                           | Andrew Down, Deputy Chief Pharmacist<br><br>Signature:  Date: 26/9/18   |
| <b>Organisational Authorisation</b>              |   |
| <b>On behalf of the organisation</b>             | Michelle Clarke, Director Nursing & Quality<br><br>Signature:  Date: 27/9/18   |
| <b>Patient Group Direction Peer Reviewed by</b>  |   |
| Mental Health Nurses                             |   |



